الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
Myeloproliferative neoplasms (MPNs) including polycythemia Vera (PV), esssential thrombocythemia (ET), primary myelofibrosis (PMF) and disorders that overlap with both myeloproliferative and myelodysplastic disorders and classified as (MDS/MPN), are clonal stem cell disorders characterized by abnormal proliferation of bone marrow (BM) stem cells, which can manifest as increased platelets, red blood cells (RBCs), or white blood cells (WBCs) in the circulation and sometimes increased fibrosis in the BM.
The occurrence of complications such as thrombotic and hemorrhagic events, bone marrow fibrosis and acute leukemia compromise patient quality of life although variable life expectancy has been reported ranging from near normal in patients with low risk ET to lower life expectancy in patients with high risk PV and PMF.
Treatment aims are to reduce the risk of thrombosis and hemorrhage, control symptoms and perhaps reduce the risk of progression. Cure is not presently possible, except in selected MF patients who are successfully receiving alloSCT.
The aim of this work was to study the epidemiology, clinical characteristics, laboratory and JAK-2V617F mutational status in Egyptian patients with Philadelphia-negative MPNs and MDS/MPNs at Hematology clinics, Internal Medicine Department, Alexandria Main University Hospital as well as Hematology clinics at Kafr El-dawar and Damanhour Health Insurance Organization and Damanhour Oncology Center, El-Beheira.. In addition, we analyzed the provided treatment options and disease- related complications with influence on patient quality of life.